Selective therapeutic interchange practices in Ontario acute care hospitals

Canadian Journal of Hospital Pharmacy

Volumn 60, Issue 5, 2007, Pages 315-318

  Bell, Chaim M ^a,b   Telio, David ^a   Goldberg, Alex F G ^c   Margulies, Alice ^b,c   Booth, Gillian L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Formulary; Pharmacy; Therapeutic interchange; Therapeutic substitution

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; CAPTOPRIL; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESOMEPRAZOLE; FLUINDOSTATIN; FOSINOPRIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LANSOPRAZOLE; LISINOPRIL; LOSARTAN; MEVINOLIN; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; VALSARTAN;

ARTICLE; CANADA; COST CONTROL; DRUG COST; DRUG FORMULARY; DRUG FORMULATION; DRUG USE; EMERGENCY CARE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; INTERHOSPITAL COOPERATION; OUTPATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; QUESTIONNAIRE;

EID: 37149029032     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hoffman JM, Shah ND, Vermeulen LC, Schumock GT, Grim P, Hunkler RJ, et al. Projecting future drug expenditures - 2006. Am J Health Syst Pharm 2006;63(2):123-138.
2. Drug costs: the solutions. Can Pharm J 1988;121(8):509, 520.
3. Wallack SS, Weinberg DB, Thomas CP. Health plans' strategies to control prescription drug spending. Health Aff (Millwood) 2004;23(6):141-148.
4. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings. American Medical Association. Am J Hosp Pharm 1994;51(14):1808-1810.
5. Gray T, Bertch K, Galt K, Gonyeau M, Karpiuk E, Oyen L, et al. Guidelines for therapeutic interchange - 2004. Pharmacotherapy 2005;25(11):1666-1680.
6. American College of Cardiology position statement therapeutic substitution [Internet]. Washington (DC): American College of Cardiology; 1988 [cited 2006 Nov 14]. Available from: http://www.acc.org/ clinical/stc/therapeutic.htm
7. Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health Syst Pharm 2002;59(6):529-533.
8. Eurich D, Poulin S, Semchuk W, Taylor J. Therapeutic interchange in Canadian hospitals: a national survey. Can J Hosp Pharm 2001;54(1):28-34.
9. Crawford SY, Myers CE. ASHP national survey of hospital-based pharmaceutical services - 1992. Am J Hosp Pharm 1993;50(7):1371-1404.
10. Antman EM, Ferguson JJ. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents? Circulation 2003;108(21):2604-2607.
11. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999;354(9185):1202-1204.
12. Galt KA, Galt MA, Sodorff M, Turner P, Lambrecht JE. Patient-perceived outcomes of an inpatient PPI therapeutic interchange program. Formulary 2001;36(5):340-354.
13. Ontario drug benefit formulary/comparative drug index. 38th ed. Toronto (ON): Ontario Ministry of Health and Long-Term Care; 2003.
14. Galt KA, Sodorff MM, Galt MA, Lambrecht JE. Impact of a hospital-based therapeutic interchange program on patients' medication access and use after discharge. P&T J 2001;26(3):151-161.
15. Burack R. Therapeutic substitution and formulary systems [letter]. Ann Intern Med 1990;113(8):640.
16. Simon GE, Psaty BM, Hrachovec JB, Mora M. Principles for evidence-based drug formulary policy. J Gen Intern Med 2005;20(10):964-968.
17. Huskamp HA, Keating NL. The new medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med 2005;20(7):662-665.
18. Clay DR, Bourg MP, Lawrence DB. Outcomes of an amlodipine-to-felodipine therapeutic interchange program. Am J Health Syst Pharm 2000;57(17):1604-1607.
19. Ross MB. Status of generic substitution: problematic drug classes reviewed. Hosp Formul 1989;24(8):441-444, 447-449.
20. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am J Hosp Pharm 1994;51(18):2279-2281